BioMarin Pharmaceutical has converted its global patent dispute with Ascendis Pharma into a royalty-bearing license for Yuviwel, a once-weekly achondroplasia treatment, resolving proceedings before the U.S. International Trade Commission and courts in several countries. Under the settlement, BioMarin will receive royalties equal to 20% of U.S. Yuviwel net sales, retroactive to the first commercial sale, and 18% of net sales in the European Union, Brazil, and South Korea through May 2030. The agreement eliminates litigation costs and uncertainty while giving BioMarin a share of Yuviwel's economics without funding its development or commercialization. However, the royalties may only partially offset cannibalization of BioMarin's Voxzogo franchise, which is expected to generate $1.0 billion to $1.05 billion in 2026 revenue. Ascendis reported €8 million in second-quarter 2026 Yuviwel revenue and over 220 unique U.S. patient enrollments through July 31, with more than 65% approved for reimbursement. The license also covers patents related to all current and potential Yuviwel indications, including hypochondroplasia and combination therapies, reducing BioMarin's future blocking leverage. The financial outcome depends on whether Yuviwel expands the treated population or primarily displaces Voxzogo sales.
Biomarin Pharmaceutical IncPatent settlement converts litigation into a royalty license (20% U.S., 18% EU/Brazil/South Korea Yuviwel sales) but may only partially offset Voxzogo cannibalization.
Ascendis Pharma AS
Chevron Corp